Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Esophageal Neoplasms × pertuzumab × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 12 Neoplasm Metastasis 3 HER2-positive Breast Cancer 2 Brain Neoplasms 2 Stomach Neoplasms 1 Solid Cancer 1 Recurrence 1 Rectal Neoplasms 1 Neoplasms 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 Liver Neoplasms 1 Inflammatory Breast Neoplasms 1 HER2-positive Early Breast Cancer 1 Gastrointestinal Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Cancer Related Cognitive Decline 1 Breast Neoplasms, Male 1 Breast Diseases 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 18 Fluorouracil 12 Docetaxel 12 Radiotherapy 11 Paclitaxel 11 Cisplatin 11 Oxaliplatin 10 Capecitabine 8 Carboplatin 7 Leucovorin 5 Cetuximab 5 Nivolumab 4 Albumin-Bound Paclitaxel 4 Trastuzumab 3 Ramucirumab 3 Interleukin-2 3 Epirubicin 3 Dexamethasone 3 130-nm albumin-bound paclitaxel 3 tremelimumab 2 tisotumab vedotin 2 regorafenib 2 patritumab deruxtecan 2 oblimersen 2 fludarabine 2 durvalumab 2 atezolizumab 2 Surgical Procedures, Operative 2 Radiation 2 Panitumumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02120911 2020-07-01

TRAP

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡